<DOC>
	<DOCNO>NCT00268359</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , bevacizumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Bevacizumab may also stop growth tumor cell block blood flow tumor . Drugs use chemotherapy , irinotecan , work different way stop growth tumor cell , either kill cell stop divide . Giving bevacizumab together irinotecan may kill tumor cell . PURPOSE : This phase II trial study side effect bevacizumab well give bevacizumab together irinotecan work treat patient recurrent refractory glioma .</brief_summary>
	<brief_title>Bevacizumab Irinotecan Treating Patients With Recurrent Refractory Gliomas</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safety bevacizumab irinotecan hydrochloride patient recurrent refractory grade 3 4 malignant glioma . Secondary - Determine activity regimen , term progression-free survival , patient . OUTLINE : Patients receive bevacizumab irinotecan hydrochloride every 2 week . Treatment continue absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 68 patient accrue study .</detailed_description>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm primary grade 3 4 malignant glioma 1 follow type : Glioblastoma multiforme Gliosarcoma Anaplastic astrocytoma Anaplastic oligodendroglioma Patients recurrent disease whose original diagnostic pathology confirm malignant glioma need rebiopsy Measurable recurrent residual primary disease contrastenhanced MRI CT scan Failed ≥ 1 prior chemotherapy regimen ( without radiotherapy ) PATIENT CHARACTERISTICS : Karnofsky performance status 60100 % Hematocrit &gt; 29 % Absolute neutrophil count &gt; 1,500/mm^3 Platelets &gt; 125,000/mm^3 Serum SGOT bilirubin &lt; 1.5 time upper limit normal Creatinine &lt; 1.5 mg/dL Urine protein : creatinine ratio ≤ 1.0 Blood pressure ≤ 150/100 mmHg No unstable angina No New York Heart Association class II great congestive heart failure No myocardial infarction within past 6 month No stroke within past 6 month No clinically significant peripheral vascular disease No evidence bleed diathesis coagulopathy No significant traumatic injury within past 28 day PRIOR CONCURRENT THERAPY : At least 4 week must elapse since prior chemotherapy radiotherapy unless unequivocal evidence tumor progression At least 6 week since prior surgical resection No previous major surgical procedure open biopsy within 28 day prior study entry No previous minor surgical procedure , fine needle aspiration , core biopsy within 7 day prior study entry No anticipate need major surgical procedure course study No concurrent aspirin , nonsteroidal antiinflammatory drug , clopidogrel</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
</DOC>